{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:06:24Z","timestamp":1789473984385,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09759-2","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:02:17Z","timestamp":1724652137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-9110","authenticated-orcid":false,"given":"P\u0131nar","family":"AYSERT-YILDIZ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-4960","authenticated-orcid":false,"given":"\u00d6zge","family":"\u00d6ZGEN-TOP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8431-6578","authenticated-orcid":false,"given":"Ahmet Furkan","family":"\u015eENT\u00dcRK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8441-168X","authenticated-orcid":false,"given":"Sait","family":"KANIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-0092","authenticated-orcid":false,"given":"Hasan Sel\u00e7uk","family":"\u00d6ZGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-0781","authenticated-orcid":false,"given":"Murat","family":"D\u0130ZBAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"11","key":"9759_CR1","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1111\/bcp.15384","volume":"88","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Li Y, Xie X, Song L, Lan G, Sun B, et al. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B. Br J Clin Pharmacol. 2022;88(11):4742\u201350. https:\/\/doi.org\/10.1111\/bcp.15384.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9759_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics8010024","volume":"8","author":"RL Nation","year":"2019","unstructured":"Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin Acute kidney Injury: Dosing and other strategies to reduce toxicity. Antibiot (Basel). 2019;8(1):24. https:\/\/doi.org\/10.3390\/antibiotics8010024.","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"9759_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/CMR.00006-08","volume":"21","author":"D Landman","year":"2008","unstructured":"Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449\u201365. https:\/\/doi.org\/10.1128\/CMR.00006-08.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"9759_CR4","doi-asserted-by":"publisher","first-page":"e02319","DOI":"10.1128\/AAC.02319-16","volume":"61","author":"AP Zavascki","year":"2017","unstructured":"Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3):e02319\u201316. https:\/\/doi.org\/10.1128\/AAC.02319-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"9759_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/MCC.0000000000001099","volume":"29","author":"I Karimzadeh","year":"2023","unstructured":"Karimzadeh I, Strader M, Kane-Gill SL, Murray PT. Prevention and management of antibiotic associated acute kidney injury in critically ill patients: new insights. Curr Opin Crit Care. 2023;29(6):595\u2013606. https:\/\/doi.org\/10.1097\/MCC.0000000000001099.","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"9759_CR6","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/cc3995","volume":"10","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. https:\/\/doi.org\/10.1186\/cc3995.","journal-title":"Crit Care"},{"issue":"4","key":"9759_CR7","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u201384. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"key":"9759_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1\u2013150. https:\/\/doi.org\/10.1038\/kisup.2012.73.","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"9759_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","volume":"72","author":"J Koch-Weser","year":"1970","unstructured":"Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857\u201368. https:\/\/doi.org\/10.7326\/0003-4819-72-6-857.","journal-title":"Ann Intern Med"},{"issue":"11","key":"9759_CR10","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1517\/14740338.2015.1088520","volume":"14","author":"T Kelesidis","year":"2015","unstructured":"Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2015;14(11):1687\u2013701. https:\/\/doi.org\/10.1517\/14740338.2015.1088520.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"9759_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","volume":"82","author":"X Liu","year":"2021","unstructured":"Liu X, Chen Y, Yang H, Li J, Yu J, Yu Z, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects. J Infect. 2021;82(2):207\u201315. https:\/\/doi.org\/10.1016\/j.jinf.2021.01.006.","journal-title":"J Infect"},{"issue":"1","key":"9759_CR12","doi-asserted-by":"publisher","first-page":"e01617","DOI":"10.1128\/AAC.01617-17","volume":"62","author":"JF John","year":"2017","unstructured":"John JF, Falci DR, Rigatto MH, Oliveira RD, Kremer TG, Zavascki AP. Severe infusion-related adverse events and renal failure in patients receiving high-dose intravenous polymyxin B. Antimicrob Agents Chemother. 2017;62(1):e01617\u201317. https:\/\/doi.org\/10.1128\/AAC.01617-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"9759_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijantimicag.2016.07.023","volume":"49","author":"KZ Vardakas","year":"2017","unstructured":"Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49(2):233\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.07.023.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"9759_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2018.11.008","volume":"94","author":"AF Oliota","year":"2019","unstructured":"Oliota AF, Penteado ST, Tonin FS, Fernandez-Llimos F, Sanches AC. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis. 2019;94(1):41\u20139. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.11.008.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"31","key":"9759_CR15","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.12998\/wjcc.v10.i31.11466","volume":"10","author":"JL Wang","year":"2022","unstructured":"Wang JL, Xiang BX, Song XL, Que RM, Zuo XC, Xie YL. Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: a meta-analysis. World J Clin Cases. 2022;10(31):11466\u201385. https:\/\/doi.org\/10.12998\/wjcc.v10.i31.11466.","journal-title":"World J Clin Cases"},{"key":"9759_CR16","doi-asserted-by":"publisher","first-page":"105328","DOI":"10.1016\/j.phrs.2020.105328","volume":"163","author":"M Sisay","year":"2021","unstructured":"Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163:105328. https:\/\/doi.org\/10.1016\/j.phrs.2020.105328.","journal-title":"Pharmacol Res"},{"issue":"1","key":"9759_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for anti-infective pharmacology (ISAP), society of critical Care Medicine (SCCM), and Society of Infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","journal-title":"Pharmacotherapy"},{"key":"9759_CR18","doi-asserted-by":"publisher","unstructured":"Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele VR, Henriksen AS, Longshaw C, Manissero D, Pecini R, Pogue JM. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021: S1198-743X(20)30764-3. https:\/\/doi.org\/10.1016\/j.cmi.2020.12.009","DOI":"10.1016\/j.cmi.2020.12.009"},{"issue":"4","key":"9759_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/aac.02634-15","volume":"60","author":"MH Rigatto","year":"2016","unstructured":"Rigatto MH, Oliveira MS, Perdig\u00e3o-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with Colistin versus Polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443\u20139. https:\/\/doi.org\/10.1128\/aac.02634-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"9759_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/antibiotics12081317","volume":"12","author":"RCL Garcia","year":"2023","unstructured":"Garcia RCL, Rodrigues RD, Garcia ECL, Rigatto MH. Comparison between Colistin and Polymyxin B in the treatment of Bloodstream infections caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-Calcoaceticus Complex. Antibiot (Basel). 2023;12(8):1317. https:\/\/doi.org\/10.3390\/antibiotics12081317.","journal-title":"Antibiot (Basel)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09759-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09759-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09759-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T18:02:11Z","timestamp":1724695331000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09759-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9759"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09759-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by Gazi University Ethics Committee with decision number 11, on June 6, 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent to participate was waived by Gazi University Ethics Committee due to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"862"}}